How Do These Analyses Contribute to Personalized Medicine?
Genomic and transcriptomic analyses are key components of personalized medicine in cancer. By identifying specific genetic mutations and gene expression changes in an individual's tumor, clinicians can tailor treatments to target those specific alterations. This approach increases the efficacy of treatments and reduces side effects. For example, patients with BRCA mutations may benefit from PARP inhibitors, while those with EGFR mutations may respond well to tyrosine kinase inhibitors.
